Proactive Investors
26 May 2026, 06:43 UTC · 2h ago
Source · https://www.proactiveinvestors.co.uk/companies/news/1092854
Read source
Search tags
Story key points
3 claims · impact-rated
Poolbeg Pharma received positive feedback from the US FDA during a pre-IND meeting for its lead asset POLB 001, including agreement on the primary endpoint for a future phase III trial. — Regulatory alignment on endpoints significantly de-risks the clinical pathway and increases the likelihood of successful future approvals.
+0.60CelLBxHealth is in advanced talks with one of the largest private US healthcare providers to deploy its Parsortix cancer diagnostic platform. — Securing a partnership with a major US provider suggests a significant scale-up in commercial adoption and revenue potential.
+0.50CelLBxHealth guided for 2026 revenues of at least £2.1 million, representing a 50% increase. — Strong revenue growth guidance provides a tangible positive signal regarding the company's financial trajectory.
+0.40Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
The company received positive feedback from the FDA and achieved alignment on the development pathway for its lead asset.
The company is in advanced talks with a large US healthcare provider and guided for a 50% increase in revenue.
No ticker relationship head found.
